1. Home
  2. CYN vs TXMD Comparison

CYN vs TXMD Comparison

Compare CYN & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyngn Inc.

CYN

Cyngn Inc.

HOLD

Current Price

$1.42

Market Cap

22.9M

Sector

Technology

ML Signal

HOLD

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

HOLD

Current Price

$2.07

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYN
TXMD
Founded
2013
2008
Country
United States
United States
Employees
62
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9M
24.3M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
CYN
TXMD
Price
$1.42
$2.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
273.8K
16.1K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
73.68
EPS
N/A
0.01
Revenue
$368,138.00
$1,761,000.00
Revenue This Year
$3,359.28
N/A
Revenue Next Year
$347.47
N/A
P/E Ratio
N/A
$212.00
Revenue Growth
N/A
35.25
52 Week Low
$1.29
$0.98
52 Week High
$41.54
$2.95

Technical Indicators

Market Signals
Indicator
CYN
TXMD
Relative Strength Index (RSI) 39.15 50.27
Support Level $1.33 $1.93
Resistance Level $1.76 $2.10
Average True Range (ATR) 0.08 0.08
MACD -0.01 0.01
Stochastic Oscillator 22.02 63.64

Price Performance

Historical Comparison
CYN
TXMD

About CYN Cyngn Inc.

Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Share on Social Networks: